Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches
International Journal of Medical Sciences · 01.01.2025 · 22 (2) · 357-370
DOI: 10.7150/ijms.102301 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Medical Sciences, erschienen am 01.01.2025. Verfasst von Zixi Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Lipoprotein(a). Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Elevated lipoprotein(a) [Lp(a)] levels are increasingly recognized as a significant risk factor for cardiovascular diseases and may also contribute to atrial fibrillation (AF). This review investigated the indirect mechanisms through which Lp(a) may influence AF, including proatherogenic, prothrombotic, and proinflammatory pathways. Traditional lipid-lowering therapies, such as lifestyle modifications and statins, have limited effects on Lp(a) levels. Emerging treatments, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipoprotein apheresis, small interfering RNA, antisense oligonucleotides, cholesterol ester transfer protein inhibitors, and interleukin-6 receptor monoclonal antibodies, are promising alternatives. Notably, only PCSK9 inhibitors and lipoprotein apheresis have been shown to reduce both Lp(a) levels and cardiovascular events. Research indicates varying associations between Lp(a) and AF across different populations, underscoring the need for diverse, large-scale studies to elucidate these differences. Ongoing trials aim to provide clearer insights into these relationships. Addressing these gaps is essential for developing targeted therapies to manage elevated Lp(a) and mitigate the risk of AF and associated cardiovascular events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China.
- Xiangya School of Medicine, Central South University, Changsha 410011, Hunan Province, People's Republic of China.
- Department of Endocrinology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, People's Republic of China.
Zitieren
APA
Zhang, Z., Peng, B., Nuranmubieke, A., Xu, Y., Liu, Y., Tu, T., Lin, Q., Wang, C., Liu, Q., & Xiao, Y. (2025). Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches. International Journal of Medical Sciences, 22(2), 357-370. https://doi.org/10.7150/ijms.102301
Vancouver
Zhang Z, Peng B, Nuranmubieke A, Xu Y, Liu Y, Tu T, et al. Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches. International Journal of Medical Sciences. 2025;22(2):357-370. doi:10.7150/ijms.102301
BibTeX
@article{Zhang2025,
author = {Zhang, Zixi and Peng, Bo and Nuranmubieke, Akedanmu and Xu, Yangfan and Liu, Yan and Tu, Tao and Lin, Qiuzhen and Wang, Cancan and Liu, Qiming and Xiao, Yichao},
title = {Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches},
journal = {International Journal of Medical Sciences},
year = {2025},
volume = {22},
number = {2},
pages = {357--370},
doi = {10.7150/ijms.102301}
}
EUVIMED